The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Regional · European Union · continued

EMA product information as a primary source — does this still hold? posts 151–151

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

KF
k.farrugiaTL3Regular19 Nov 2024#151

On post #147 — agreed on the reasoning, with one qualification.

Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.

21 likes 20mo
This topic was closed 45 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.
Moved from North America by t.vasquez. Category placement is not obvious from outside and getting it wrong is expected. This topic will get better answers here. The move is recorded in the public log citing R7.

Suggested topics

TopicParticipantsRepliesViewsActivity
EU-wide position versus national implementation
EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category…
BBCLSGLEVK+22 29 356 11mo
Cross-border purchase rules within the EU
On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what determines the answer.…
HMEFVKGZA+45 49 15k 8mo
Reimbursement variation across member states
Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
SFJSREBS+7 11 39k 3mo
Revisiting: German, French and Dutch differences, compared
Posting this under the heading it deserves: Revisiting: German, French and Dutch differences, compared Everything below is what sits behind that. A coverage question with the paperwork detail included, since…
ITKSTHEDS+90 99 32k 9mo
German, French and Dutch differences, compared
German, French and Dutch differences, compared — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…
AKMMR 2 12k 10h

Related topics — sharing the tags EMA, cost per milligram, formulary

TopicParticipantsRepliesViewsActivity
Coverage for the indication versus for the drug
Coverage for the indication versus for the drug — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…
AAAKEFHJG+70 79 18k 14mo
Follow-up: External review after an internal denial
Posting this under the heading it deserves: External review after an internal denial Everything below is what sits behind that. A coverage question with the paperwork detail included, since that is what…
RVIWBENK+6 10 12k 15h
Pharmaceutical compounding rules, summarised from primary sources
Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…
BJMBEDRIIL+135 163 46k 17mo
Substitution between formats during a shortage — what changed since
Substitution between formats during a shortage — what changed since — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is…
SBKACONKWN+17 21 2.7k 9d
Personal import allowances, compared — a second dataset
Personal import allowances, compared — a second dataset — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what…
CCJHKSAVN+124 132 9.2k 2mo